(RTTNews) - Today's Daily Dose brings you news about Alnylam Pharma's phase III ATLAS program for Fitusiran in patients with hemophilia A and B; Elite's pivotal bioequivalence fed study for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback